ST Elevation Myocardial Infarction Clinical Trial
Official title:
Impact of the Glycemic State on the in Hospital and Short Term Outcomes of Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Angioplasty
ST-elevation myocardial infarction is a major cause of morbidity and mortality worldwide. ST-elevation myocardial infarction damages the regional myocardium that undergoes ischemia and necrosis, resulting in impairment of both systolic and diastolic functions of the heart. Left ventricular function and myocardial infarct size both serve as the main determinants Of patients' outcome after myocardial infarction. Timely management of ST-elevation myocardial infarction, using reperfusion therapy, including fibrinolysis and primary percutaneous coronary intervention, leads to a better outcome for these patients.
Reperfusion failure is attributed to different factors, including diabetes. Several
mechanisms have been proposed for the harmful effects of hyperglycemia after acute myocardial
infarction. Association of hyperglycemia with the activation of blood coagulation has been
well studied; it could induce a shortening of the fibrinogen half-life, increase in
fibrinopeptide A, fragments of pro-thrombin in factor VII, and platelet aggregation, all of
which could lead to increased activation of thrombosis. Hyperglycemia at admission is
associated with increased levels of inflammatory markers, enhanced expression of cytotoxic
T-cells, and reduced expression of cytotoxic T-lymphocyte-associated protein 4, indicating
its association with increased inflammatory immune process after acute myocardial infarction.
It also could be associated with endothelial dysfunction, oxidative stress, and possibly,
abolition of protective ischemic preconditioning. Other possible mechanism of harmful effects
of acute hyperglycemia is microvascular dysfunction after coronary revascularization.
Studying the influence of diabetes mellitus on clinical outcome in the thrombolytic era of
acute myocardial infarction, GUSTO-I trial showed that patients with diabetes mellitus have a
significantly increased risk of both early and late mortality, which may be attributed to
more advanced coronary artery disease and co-morbidities.
Results of the HORIZONS-AMI study showed that patients with newly diagnosed diabetes mellitus
had similarly poor prognosis after primary percutaneous coronary intervention in ST-elevation
myocardial infarction patients as those with previously established diabetes mellitus, newly
diagnosed diabetes mellitus was based on HgbA1c levels following admission and did not assess
for blood glucose levels at admission or during hospital stay.
Regarding the effect of diabetes mellitus on left ventricular systolic function, diabetic
patients with first ST-elevation myocardial infarction had reduced left ventricular systolic
function, measured with speckle-tracking strain, compared with non-diabetic patients at
baseline and at 6-month follow up, despite similar left ventricular ejection fraction in both
groups. Similarly, according to the ischemic cascade, diastolic function is expected to be
affected with variable degrees among diabetic, prediabetic and non-diabetic ST-elevation
myocardial infarction patients.
Timmer et al, studied the effect of admission stress hyperglycemia and that of chronic
hyperglycemia (elevated levels of HbA1c in patients with undiagnosed diabetes mellitus) on
ST-elevation myocardial infarction patients undergoing primary percutaneous coronary
intervention; both elevated glucose and HbA1c levels were associated with adverse outcomes.
However elevated glucose but not elevated HbA1c was associated with larger enzymatic infarct
size and high early mortality.
Furthermore, Ota et al, demonstrated the association between stress hyperglycemia and the
development of microvascular obstruction using late gadolinium enhancement - cardiovascular
magnetic resonance imaging, suggesting that hyperglycemic control immediately after admission
might reduce the incidence of microvascular obstruction.
This study is designed to explore the impact of the glycemic state on the in-hospital and
short term outcomes of patients with ST-elevation myocardial infarction undergoing
reperfusion therapy in two separate arms; those with known diabetes mellitus and those
without known diagnosis of diabetes mellitus, and then comparing results among those with
controlled diabetes mellitus, uncontrolled diabetes mellitus and newly diagnosed diabetes
mellitus.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05601999 -
Study of Efficacy and Safety of GNR-060 vs Metalyse in Patients With ST Elevation Myocardial Infarction
|
Phase 3 | |
Recruiting |
NCT06147986 -
Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells as an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) Patients
|
Phase 2 | |
Not yet recruiting |
NCT05881382 -
Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction
|
Phase 3 | |
Enrolling by invitation |
NCT02615015 -
SNPs in the DNase 1 Gene Impair Its Activity and Are Increased in a STE-ACS Patient Cohort Compared to Healthy Controls
|
N/A | |
Recruiting |
NCT05812963 -
IVUS Versus FFR for Non-infarct Related Artery Lesions in Patients With Multivessel Disease and Acute STEMI
|
N/A | |
Recruiting |
NCT05554588 -
Intrathrombus Thrombolysis Versus Aspiration Thrombectomy During Primary PCI
|
N/A | |
Recruiting |
NCT05450757 -
Shanghai ST-segment Elevation Myocardial Infarction Cohort
|
||
Active, not recruiting |
NCT03278509 -
Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART)
|
Phase 4 | |
Completed |
NCT03156699 -
The Incidence, Effect and Persistence of Fragmented-QRS, in Patients Presenting With ST-Elevation Myocardial Infarction
|
||
Not yet recruiting |
NCT03263468 -
Revascularization StrategIes for ST Elevation Myocardial Infarction Trial
|
N/A | |
Not yet recruiting |
NCT03266328 -
Procedure and In-hospital Outcome of Patients Under 40 Years Old Undergoing Primary Percutaneous Coronary Intervention for Acute ST Elevated Myocardial Infarction in Assiut University
|
N/A | |
Enrolling by invitation |
NCT04970238 -
Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction
|
Phase 4 | |
Recruiting |
NCT02557217 -
NP202 for Treatment of Post -STEMI Left Ventricular Systolic Dysfunction
|
Phase 2 | |
Recruiting |
NCT02224534 -
Ticagrelor Versus Clopidogrel in Left Ventricular Remodeling After ST-segment Elevation Myocardial Infarction
|
Phase 4 | |
Completed |
NCT01136187 -
Trial Comparing Radial and Femoral Approach in Primary Percutaneous Coronary Intervention (PCI)
|
N/A | |
Not yet recruiting |
NCT04068116 -
Impact of Ischemic Post-conditioning
|
N/A | |
Not yet recruiting |
NCT04063345 -
Long-term Clinical Outcomes of intraVascular Ultrasound-guided vs Angiography-guided Primary pErcutaneous Intervention in Patients With Acute ST Segment Elevated Myocardial Infarction
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03646357 -
BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic Function
|
Phase 4 | |
Completed |
NCT03984071 -
The Predictive Value of eGFR for Adverse Cardiovascular Events in Patients With STEMI
|
||
Completed |
NCT03740776 -
The Eosinophils Percentage Predicts In-hospital Major Adverse Cardiac Events in STEMI Patients After PCI
|